Research programme: antibody therapeutics - Incendia Therapeutics/XtalPi
Latest Information Update: 11 Sep 2023
At a glance
- Originator Parthenon Therapeutics; XtalPi
- Developer Incendia Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 05 Sep 2023 Parthenon Therapeutics and XtalPi enter into an agreement to discover and develop antibody therapeutics
- 05 Sep 2023 Early research in Solid tumours in China (unspecified route), prior to September 2023
- 05 Sep 2023 Early research in Solid tumours in USA (unspecified route), prior to September 2023